What is Opus Genetics?
Opus Genetics is a clinical-stage biopharmaceutical company operating at the intersection of biotechnology and ophthalmology. The company is dedicated to pioneering innovative gene therapies for inherited retinal diseases and other complex retinal and refractive disorders. Headquartered in the United States, Opus Genetics focuses its research and development efforts on creating novel treatments designed to correct or compensate for genetic defects that lead to retinal degeneration. Their mission is to translate cutting-edge scientific discoveries into safe and effective therapeutic solutions for patients suffering from both rare and common retinal conditions, aiming to establish a leadership position in global ophthalmic gene therapy innovation.
How much funding has Opus Genetics raised?
Opus Genetics has raised a total of $164.4M across 2 funding rounds:
Angel/Seed
$4.5M
Stock/Share Issuance
$159.9M
Angel/Seed (2023): $4.5M with participation from North Carolina Biotechnology Center
Stock/Share Issuance (2026): $159.9M led by Oberland Capital
Key Investors in Opus Genetics
Oberland Capital
Oberland Capital is a private investment firm specializing in healthcare innovation, managing substantial assets and offering flexible financing solutions for companies in the sector. Their focus on significant capital investments between $50 million and $300 million indicates a strategic interest in advancing late-stage development and commercialization efforts.
North Carolina Biotechnology Center
The North Carolina Biotechnology Center is a key player in life science economic development, supporting the transformation of research into marketable products. Their involvement suggests a commitment to fostering innovation and commercialization within the biopharmaceutical and therapeutic sectors.
What's next for Opus Genetics?
With the recent major strategic investment and a substantial total funding amount of $164.4M, Opus Genetics is poised to accelerate its development pipeline and expand its research initiatives. This significant capital infusion is expected to fuel the advancement of its gene therapy programs through clinical trials and towards potential commercialization. The company's focus on addressing unmet needs in inherited retinal diseases positions it to capture a significant share of the growing ophthalmic gene therapy market. Strategic partnerships and continued investment in R&D will be crucial for Opus Genetics to maintain its trajectory and deliver on its promise of vision-preserving and vision-restoring therapies.
See full Opus Genetics company page
